Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Deal Watch 2021

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Seagen Inc. will take advantage of its experience with the kinase inhibitor Tukysa (tucatinib), approved in the US last year for HER2-positive breast cancer, by partnering with RemeGen Ltd. on development and commercialization of the HER2-targeted antibody-drug conjugate (ADC) disitamab vedotin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business